PCSK9 Inhibitors: all 193 studies that test it
Page 1 of 2. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque RemodelingNot yet recruitingNCT07819643Phase 4
- A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaNot yet recruitingNCT07803679Phase 4
- Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial HypercholesterolemiaNot yet recruitingNCT07775339Phase 3
- CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACSRecruitingNCT07612774Phase 4
- Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid PlaqueNot yet recruitingNCT07586540Phase 3
- Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary PreventionRecruitingNCT07581808Phase 4
- Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute PancreatitisRecruitingNCT07388420Not applicable
- PCSK9 Inhibitors in the Treatment of Calcific Aortic StenosisNot yet recruitingNCT07256197Phase 3
- Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHEnrolling by invitationNCT07102511Phase 3
- A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaRecruitingNCT06568471Phase 3
- A Study on Evaluating the Safety of HST101 in Healthy Chinese ParticipantsEnrolling by invitationNCT06504043Phase 1
- TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingNCT06385262Phase 2
- Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial InfarctionRecruitingNCT06364124Not applicable
- Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid MetabolismNot yet recruitingNCT06140095Early Phase 1
- The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid ProfileNot yet recruitingNCT06083961Phase 4
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAANot yet recruitingNCT06081153Early Phase 1
- Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)Not yet recruitingNCT06080256Phase 3
- Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and CancerNot yet recruitingNCT05976893Phase 4
- Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)RecruitingNCT05741086Phase 3
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1RecruitingNCT05641753Phase 4
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNCT05587621Not applicable
- High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized StudyRecruitingNCT05585151Phase 4
- Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium InfarctionRecruitingNCT05292404Phase 4
- The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV RiskRecruitingNCT05152888Phase 4
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionEnrolling by invitationNCT04798430Phase 3
- Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy DrinkersRecruitingNCT04781322Phase 1
- Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary SyndromeRecruitingNCT04719221Phase 4
- Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant RecipientsRecruitingNCT04193306Phase 4
- A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCTerminatedNCT05144529Phase 2Results posted
- Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C ReductionCompletedNCT04797104Phase 3Results posted
- Effect of Evolocumab on Coronary Plaque CharacteristicsCompletedNCT04710368Phase 4Results posted
- Lipid Management in Renal Transplant Recipients Using Evolocumab.CompletedNCT04608474Phase 4Results posted
- Reducing Intracranial atheroSclErosis With RepathaTerminatedNCT04573777Phase 4Results posted
- Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 InhibitorsCompletedNCT04189484Phase 1Results posted
- Evolocumab in Patients With Acute MICompletedNCT04082442Phase 2Results posted
- Impact of Evolocumab in Cardiac Transplant Patients With CAVCompletedNCT03944577Phase 2Results posted
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeCompletedNCT03872401Phase 3Results posted
- The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular DiseaseCompletedNCT03829046Phase 4Results posted
- Long Term Safety Study of PRALUENTTerminatedNCT03694197Phase 4Results posted
- Effect of Evolocumab on Coronary AtherosclerosisCompletedNCT03689946Phase 3Results posted
- Imaging of Coronary Plaques in Participants Treated With EvolocumabCompletedNCT03570697Phase 3Results posted
- Cardiac Allograft Vasculopathy Inhibition With AlirocumabCompletedNCT03537742Phase 2Results posted
- Evolocumab in Acute Coronary SyndromeCompletedNCT03515304Phase 2Results posted
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompletedNCT03510884Phase 3Results posted
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT03510715Phase 3Results posted
- Effect of Evolocumab on Coronary Endothelial FunctionCompletedNCT03500302Phase 2Results posted
- Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed DyslipidemiaTerminatedNCT03433755Phase 3Results posted
- Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial HypercholesterolemiaCompletedNCT03403374Phase 4Results posted
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
- Impact of LDL-cholesterol Lowering on Platelet ActivationTerminatedNCT03331666Phase 4Results posted
- Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes MellitusTerminatedNCT03258281Phase 4Results posted
- Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT03156621Phase 3Results posted
- Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet ReactivityCompletedNCT03096288Phase 4Results posted
- Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European CountriesTerminatedNCT03080935Phase 3Results posted
- Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With HypercholesterolemiaCompletedNCT02984982Phase 4Results posted
- Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to PlaceboCompletedNCT02957682Phase 4Results posted
- Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 DiabetesCompletedNCT02948777Phase 4Results posted
- Alirocumab in Patients With Acute Myocardial InfarctionCompletedNCT02938949Phase 4Results posted
- An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompletedNCT02890992Phase 2Results posted
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label ExtensionCompletedNCT02867813Phase 3Results posted
- Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed DyslipidemiaCompletedNCT02833844Phase 3Results posted
- Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed DyslipidemiaCompletedNCT02739984Phase 3Results posted
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))CompletedNCT02729025Phase 3Results posted
- Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With HypercholesterolemiaCompletedNCT02715726Phase 3Results posted
- Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed DyslipidemiaCompletedNCT02662569Phase 3Results posted
- Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)CompletedNCT02642159Phase 4Results posted
- Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)CompletedNCT02624869Phase 3Results posted
- Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)CompletedNCT02585778Phase 3Results posted
- Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of StatinCompletedNCT02584504Phase 3Results posted
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)CompletedNCT02476006Phase 3Results posted
- Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) DisordersCompletedNCT02392559Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis TherapyCompletedNCT02326220Phase 3Results posted
- Open-label Extension (OLE) Study to Assess Safety and Efficacy of EvolocumabCompletedNCT02304484Phase 3Results posted
- Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of EvolocumabCompletedNCT02275156Phase 1Results posted
- Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk SubjectsCompletedNCT02207634Phase 3Results posted
- Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal AntibodyCompletedNCT02189837Phase 3Results posted
- Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)CompletedNCT02107898Phase 3Results posted
- Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)CompletedNCT02023879Phase 3Results posted
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3CompletedNCT01984424Phase 3Results posted
- Open Label Study of Long Term Safety Evaluation of AlirocumabCompletedNCT01954394Phase 3Results posted
- Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular RiskCompletedNCT01953328Phase 3Results posted
- Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)CompletedNCT01926782Phase 3Results posted
- Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/PenCompletedNCT01879319Phase 3Results posted
- Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed DyslipidemiaCompletedNCT01854918Phase 3Results posted
- Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/PenCompletedNCT01849497Phase 3Results posted
- GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular UltrasoundCompletedNCT01813422Phase 3Results posted
- Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in JapanCompletedNCT01812707Phase 2Results posted
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated RiskCompletedNCT01764633Phase 3Results posted
- Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2CompletedNCT01763918Phase 3Results posted
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2CompletedNCT01763905Phase 3Results posted
- LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2CompletedNCT01763866Phase 3Results posted
- Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2CompletedNCT01763827Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)CompletedNCT01730053Phase 3Results posted
- Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)CompletedNCT01730040Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)CompletedNCT01709513Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)CompletedNCT01709500Phase 3Results posted
- ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabCompletedNCT01663402Phase 3Results posted
- A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese SubjectsCompletedNCT01652703Phase 2Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With HypercholesterolemiaCompletedNCT01644474Phase 3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)CompletedNCT01644188Phase 3Results posted